ArticleFrontiers in immunology2026
Single-cell landscape of lymphoid and myeloid heterogeneity across type-stratified craniofacial lesions in polyostotic fibrous dysplasia.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polyostotic fibrous dysplasia (POFD) is a mosaic skeletal disorder driven by somatic Methods: We performed single-cell RNA sequencing on maxillary lesion tissues from three age- and sex-matched POFD patients classified as Type I (n=1), Type II (n=1), and Type III (n=1). After stringent quality control, 24,567 cells (median 1,762 genes/cell) were integrated and clustered. Ligand-receptor interactions were inferred using CellChat. Results: Four major lineages were resolved: mesenchyme, lymphoid, myeloid, endovascular. Lymphoid representation differed across subtypes (Type I 1.00%, Type II 5.10%, Type III 10.90%), whereas endovascular fractions showed an inverse pattern (Type I 25.10%, Type II 9.90%, Type III 4.50%). Sub-clustering identified five lymphoid and six myeloid subsets. CD4 Conclusions: This study provides the first single-cell immune atlas of POFD, delineating lymphoid and myeloid heterogeneity across three histological subtypes. The identified subtype-specific markers and inter-cellular communication architectures offer candidate biomarkers for diagnostic stratification and reveal potential immunomodulatory targets for this disfiguring bone disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.